<DOC>
	<DOCNO>NCT00829439</DOCNO>
	<brief_summary>This study design determine high dose levodopa/carbidopa tolerate without serious side effect child Angelman syndrome . It hypothesize levodopa may lead improvement neurodevelopment abnormal movement ( e.g . tremor ) child Angelman syndrome . Data study use design phase II trial determine efficacy levodopa treat child Angelman syndrome .</brief_summary>
	<brief_title>Study Tolerability Levodopa/Carbidopa Children With Angelman Syndrome</brief_title>
	<detailed_description>Levodopa prodrug `` delivers '' dopamine brain . It usually give carbidopa , peripheral decarboxylase inhibitor , increase bioavailability levodopa . Animal study suggest levodopa reverse excess phosphorylation enzyme involve synaptic neuronal function , include calcium/calmodulin-dependent kinase type 2 ( CaMKII ) . Recently , show excess phosphorylation CaMKII may responsible neurological deficit see Angelman syndrome . Therefore , hypothesize levodopa may lead improvement neurodevelopment abnormal movement ( e.g . tremor ) child Angelman syndrome . Although many child use levodopa variety medical condition last 30 year , approve Food Drug Administration ( FDA ) use child , formally study child Angelman syndrome , know dose levodopa appropriate child Angelman syndrome . Therefore , purpose study find high dose levodopa child Angelman syndrome tolerate without serious side effect . Once know dose levodopa tolerate child Angelman syndrome , conduct large follow-up study find whether levodopa lead improvement development tremor .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Angelman Syndrome</mesh_term>
	<mesh_term>Carbidopa</mesh_term>
	<mesh_term>Levodopa</mesh_term>
	<mesh_term>Carbidopa , levodopa drug combination</mesh_term>
	<criteria>Angelman syndrome , confirm molecular testing Must willing come research visit 2 day , exactly 1 week apart On levodopa , carbidopa , dopamine agonist 2 week prior participation Other medical condition may associate developmental cognitive delay More 2 clinical seizure per month Used monoamine oxidase ( MAO ) inhibitor within last 2 week Used phenytoin within last 2 week Used phenothiazine , butyrophenones , thioxanthenes within last 2 week Hypersensitive levodopa carbidopa Cardiovascular disease instability Respiratory disease , include asthma , emphysema , chronic cough , shortness breath Liver disease Stomach intestinal ulcer Kidney disease Hematological problem , include anemia , leucopenia , thrombocytopenia Used investigational drugs/interventions within past three month</criteria>
	<gender>All</gender>
	<minimum_age>4 Years</minimum_age>
	<maximum_age>12 Years</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Angelman syndrome</keyword>
	<keyword>Levodopa</keyword>
	<keyword>Carbidopa</keyword>
	<keyword>L-dopa</keyword>
</DOC>